Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dositinib mesylate
- Development stage
- Phase 2
- Lead developer
- Genuine Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dositinib mesylate is an orally bioavailable small molecule inhibitor of the epidermal growth factor receptor (EGFR), developed by Henan Genuine Biotech Co., Ltd. It is specifically designed to target EGFR mutations in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). By inhibiting the tyrosine kinase activity of mutated EGFR, dositinib blocks downstream signaling pathways that drive tumor cell proliferation and survival. The drug is currently being evaluated in Phase I/II clinical trials to determine its safety, pharmacokinetics, and preliminary efficacy as a monotherapy and in combination with other agents such as GEN-725.
- Other names
- dositinib
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on dositinib mesylate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dositinib mesylate.